View Older Stories View More Recent Stories
-
Piper Sandler on Natera (NTRA): 'IMvigor011 Changes the Game in More Ways than Expected'
-
Natera loses patent ruling in NeoGenomics litigation
-
Natera's Signatera test selected for bladder cancer trial
-
Natera launches AI foundation models for oncology drug development
-
UBS Reiterates Buy Rating on Natera (NTRA)
-
Natera's Signatera test shows positive results in bladder cancer trial
-
Natera (NTRA) PT Raised to $255 at RBC Capital
-
Natera (NTRA) PT Raised to $205 at Bernstein SocGen Group
-
Natera (NTRA) PT Raised to $215 at TD Cowen
-
Natera (NTRA) Misses Q2 EPS by 12c; offers guidance
-
Natera launches noninvasive prenatal test for inherited conditions
-
Evercore ISI Starts Natera (NTRA) at Outperform
-
BTIG names top large-cap picks for second half of 2025
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Leerink Partners Reiterates Outperform Rating on Natera (NTRA)
-
Natera (NTRA) Announces Medicare Coverage for Signatera Genome
-
RBC Capital on Natera (NTRA): 'Beats Never Looked So Good'
-
Natera (NTRA) PT Raised to $200 at TD Cowen Following Sales Beat
-
Natera (NTRA) Tops Q1 EPS by 14c, provides guidance
-
Natera (NTRA) Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test
-
Increasing unusual put option volume: TKO LW NTRA XLI JNPR KBE
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Natera (NTRA) Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
-
TD Cowen on Natera (NTRA): '2025 Guide Hits on Many Fronts, Setting Up for Another Strong Year'
-
Natera (NTRA) PT Raised to $195 at Canaccord Genuity
-
Natera (NTRA) Tops Q4 EPS by 8c, provides guidance
-
Natera (NTRA) Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Raymond James Reiterates Outperform Rating on Natera (NTRA)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Barclays Starts Natera (NTRA) at Overweight
-
Natera (NTRA): Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
-
Natera (NTRA) PT Raised to $195 at TD Cowen; 'Solid Momentum Set to Continue'
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Natera (NTRA) Issues Statement on Guardant Health Litigation
-
Natera (NTRA) PT Raised to $200 at Piper Sandler
-
Natera (NTRA) PT Raised to $175 at TD Cowen
-
Natera (NTRA) PT Raised to $160 at Baird
-
Natera (NTRA) PT Raised to $182 at Jefferies
-
Natera (NTRA) Tops Q3 EPS by 31c, Beats on Revenue; Offers FY24 Revenue Guidance
-
Natera (NTRA) Tops Q3 EPS by 31c; raises outlook
-
Natera (NTRA) PT Raised to $150 at Canaccord Genuity
-
Natera (NTRA) Reports Court Ordered Permanent Injunction Against NeoGenomics' Accused RaDaR Assay
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
TD Cowen Reiterates Buy Rating on Natera (NTRA)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera (NTRA) PT Raised to $145 at Canaccord Genuity
-
Natera (NTRA) PT Raised to $145 at TD Cowen
-
Natera (NTRA) PT Raised to $120 at Baird
-
Natera (NTRA) Tops Q2 EPS by 39c, provides guidance

